Market Cap 15.12B
Revenue (ttm) 502.08M
Net Income (ttm) -724.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -144.39%
Debt to Equity Ratio -0.85
Volume 3,179,400
Avg Vol 3,530,824
Day's Range N/A - N/A
Shares Out 195.86M
Stochastic %K 99%
Beta 0.95
Analysts Strong Sell
Price Target $104.80

Company Profile

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 391 9740
Address:
3160 Porter Drive, Suite 250, Palo Alto, United States
LMXPERTEN
LMXPERTEN Jul. 3 at 6:25 AM
$BBIO financing longterm secured. 3 drugs on way to market. 3 hidden PRVs (ok not a lot but still 600 MUSD).
0 · Reply
Nomorelies
Nomorelies Jul. 3 at 2:25 AM
$BBIO ❤️❤️❤️
0 · Reply
WAJeff
WAJeff Jul. 2 at 3:54 PM
$BBIO Nice to see this moving again
0 · Reply
Nomorelies
Nomorelies Jul. 2 at 3:17 PM
$BBIO Strong hold
0 · Reply
Cap_00
Cap_00 Jul. 2 at 2:16 PM
$BBIO This should be the next big Buy Out for the Big Pharma.
0 · Reply
sampeper
sampeper Jul. 2 at 12:22 PM
$BBIO BridgeBio drug shows kidney benefits in heart disease study https://www.streetinsider.com/dr/news.php?id=26724050&gfv=1
0 · Reply
sampeper
sampeper Jul. 2 at 12:19 PM
$BBIO great news: Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM https://www.stocktitan.net/news/BBIO/acoramidis-associated-with-first-ever-early-and-sustained-direct-v46fdm3k3tdm.html
0 · Reply
BioRich
BioRich Jul. 1 at 4:41 PM
$VKTX Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) $OCUL 18) $SOFI 19) $BBIO 20) $SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
BullNavigatorr
BullNavigatorr Jul. 1 at 2:08 PM
$BBIO is drawing attention after announcing a $1B preferred equity raise at a pivotal stage in its pipeline expansion. The financing comes as Attruby continues scaling toward blockbuster potential, while the company positions itself for multiple upcoming U.S. product launches across key rare disease programs including BBP-418, encaleret, and infigratinib. The market takeaway is a classic biotech capital structure tradeoff: dilution today in exchange for accelerated commercial readiness tomorrow. With multiple late-stage catalysts stacked within a 12-month window, sentiment is increasingly tied to execution probability rather than just pipeline optionality.
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:47 PM
$BBIO (-0.3% pre) BridgeBio gets $1B from Sixth Street, HCRx for three launches https://ooc.bz/l/106641
0 · Reply
Latest News on BBIO
BridgeBio announces PROPEL 3 trial met primary endpoint

2026-06-28T23:10:05.000Z - 5 days ago

BridgeBio announces PROPEL 3 trial met primary endpoint


BridgeBio Pharma Slides: Conference presentation

Jun 28, 2026, 7:00 AM EDT - 6 days ago

BridgeBio Pharma Slides: Conference presentation


BridgeBio Pharma Transcript: AGM 2026

Jun 22, 2026, 2:00 PM EDT - 12 days ago

BridgeBio Pharma Transcript: AGM 2026


BridgeBio price target lowered to $96 from $106 at Mizuho

2026-06-16T11:25:24.000Z - 18 days ago

BridgeBio price target lowered to $96 from $106 at Mizuho


Canaccord starts BridgeBio on Attruby launch, pipeline

2026-06-03T11:44:52.000Z - 4 weeks ago

Canaccord starts BridgeBio on Attruby launch, pipeline


BridgeBio Pharma Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 4 weeks ago

BridgeBio Pharma Slides: Corporate presentation


BridgeBio initiated with a Buy at Canaccord

2026-06-03T10:13:20.000Z - 4 weeks ago

BridgeBio initiated with a Buy at Canaccord


BridgeBio initiated with a Neutral at Citi

2026-05-18T20:22:46.000Z - 6 weeks ago

BridgeBio initiated with a Neutral at Citi


BridgeBio shares have ‘clear path’ to $90s, says JPMorgan

2026-05-12T13:20:39.000Z - 7 weeks ago

BridgeBio shares have ‘clear path’ to $90s, says JPMorgan


BridgeBio price target raised to $130 from $125 at Evercore ISI

2026-05-08T18:38:04.000Z - 2 months ago

BridgeBio price target raised to $130 from $125 at Evercore ISI


BridgeBio price target raised to $114 from $100 at Bernstein

2026-05-08T11:59:17.000Z - 2 months ago

BridgeBio price target raised to $114 from $100 at Bernstein


BridgeBio Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

BridgeBio Pharma Earnings Call Transcript: Q1 2026


BridgeBio Pharma Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

BridgeBio Pharma Earnings release: Q1 2026


BridgeBio Pharma Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

BridgeBio Pharma Quarterly report: Q1 2026


BridgeBio Pharma Slides: Corporate presentation

May 7, 2026, 4:00 PM EDT - 2 months ago

BridgeBio Pharma Slides: Corporate presentation


BridgeBio to Participate in May and June Investor Conferences

May 6, 2026, 4:01 PM EDT - 2 months ago

BridgeBio to Participate in May and June Investor Conferences


BridgeBio Pharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

BridgeBio Pharma Proxy statement: Proxy filing


BridgeBio Pharma Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

BridgeBio Pharma Proxy statement: Proxy filing


BridgeBio Pharma Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 4 months ago

BridgeBio Pharma Slides: Corporate presentation


BridgeBio Pharma Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

BridgeBio Pharma Earnings Call Transcript: Q4 2025


BridgeBio Pharma Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

BridgeBio Pharma Annual report: Q4 2025


BridgeBio Pharma Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 4 months ago

BridgeBio Pharma Earnings release: Q4 2025


BridgeBio to Participate in March Investor Conferences

Feb 23, 2026, 7:30 AM EST - 4 months ago

BridgeBio to Participate in March Investor Conferences


BridgeBio Pharma Transcript: Study result

Feb 12, 2026, 8:00 AM EST - 5 months ago

BridgeBio Pharma Transcript: Study result


BridgeBio Pharma Press release: Study result

Feb 12, 2026, 8:00 AM EST - 5 months ago

BridgeBio Pharma Press release: Study result


BridgeBio Pharma Slides: Study result

Feb 12, 2026, 8:00 AM EST - 5 months ago

BridgeBio Pharma Slides: Study result


BridgeBio Pharma Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

BridgeBio Pharma Slides: Corporate presentation


BridgeBio Pharma Transcript: Investor Update

Jan 9, 2026, 8:00 AM EST - 6 months ago

BridgeBio Pharma Transcript: Investor Update


BridgeBio Pharma Slides: Investor Update

Jan 9, 2026, 8:00 AM EST - 6 months ago

BridgeBio Pharma Slides: Investor Update


BridgeBio to Participate in December Investor Conferences

Nov 25, 2025, 7:30 AM EST - 7 months ago

BridgeBio to Participate in December Investor Conferences


BridgeBio to Participate in November Investor Conferences

Nov 4, 2025, 7:30 AM EST - 8 months ago

BridgeBio to Participate in November Investor Conferences


BridgeBio Pharma Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

BridgeBio Pharma Earnings Call Transcript: Q3 2025


BridgeBio Pharma Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

BridgeBio Pharma Quarterly report: Q3 2025


BridgeBio Pharma Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

BridgeBio Pharma Earnings release: Q3 2025


BridgeBio Pharma Slides: Corporate Presentation

Oct 29, 2025, 4:00 PM EDT - 8 months ago

BridgeBio Pharma Slides: Corporate Presentation


BridgeBio Pharma Transcript: Study Result

Oct 29, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Transcript: Study Result


BridgeBio Pharma Press release: Study Result

Oct 29, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Press release: Study Result


BridgeBio Pharma Slides: Study Result

Oct 29, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Slides: Study Result


BridgeBio Pharma Transcript: Study Result

Oct 27, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Transcript: Study Result


BridgeBio Pharma Press release: Study Result

Oct 27, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Press release: Study Result


BridgeBio Pharma Slides: Study Result

Oct 27, 2025, 8:00 AM EDT - 8 months ago

BridgeBio Pharma Slides: Study Result


BridgeBio Pharma Transcript: Investor Update

Sep 10, 2025, 8:00 AM EDT - 10 months ago

BridgeBio Pharma Transcript: Investor Update


BridgeBio Pharma Slides: Investor Update

Sep 10, 2025, 8:00 AM EDT - 10 months ago

BridgeBio Pharma Slides: Investor Update


BridgeBio to Participate in September Investor Conferences

Aug 27, 2025, 7:30 AM EDT - 11 months ago

BridgeBio to Participate in September Investor Conferences


BridgeBio Pharma Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

BridgeBio Pharma Earnings Call Transcript: Q2 2025


BridgeBio Pharma Quarterly report: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

BridgeBio Pharma Quarterly report: Q2 2025


BridgeBio Pharma Earnings release: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 11 months ago

BridgeBio Pharma Earnings release: Q2 2025


LMXPERTEN
LMXPERTEN Jul. 3 at 6:25 AM
$BBIO financing longterm secured. 3 drugs on way to market. 3 hidden PRVs (ok not a lot but still 600 MUSD).
0 · Reply
Nomorelies
Nomorelies Jul. 3 at 2:25 AM
$BBIO ❤️❤️❤️
0 · Reply
WAJeff
WAJeff Jul. 2 at 3:54 PM
$BBIO Nice to see this moving again
0 · Reply
Nomorelies
Nomorelies Jul. 2 at 3:17 PM
$BBIO Strong hold
0 · Reply
Cap_00
Cap_00 Jul. 2 at 2:16 PM
$BBIO This should be the next big Buy Out for the Big Pharma.
0 · Reply
sampeper
sampeper Jul. 2 at 12:22 PM
$BBIO BridgeBio drug shows kidney benefits in heart disease study https://www.streetinsider.com/dr/news.php?id=26724050&gfv=1
0 · Reply
sampeper
sampeper Jul. 2 at 12:19 PM
$BBIO great news: Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM https://www.stocktitan.net/news/BBIO/acoramidis-associated-with-first-ever-early-and-sustained-direct-v46fdm3k3tdm.html
0 · Reply
BioRich
BioRich Jul. 1 at 4:41 PM
$VKTX Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) $OCUL 18) $SOFI 19) $BBIO 20) $SGP 21) VNDA 22) SHAZ 23) NRXP 24) GPCR 25) EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
BullNavigatorr
BullNavigatorr Jul. 1 at 2:08 PM
$BBIO is drawing attention after announcing a $1B preferred equity raise at a pivotal stage in its pipeline expansion. The financing comes as Attruby continues scaling toward blockbuster potential, while the company positions itself for multiple upcoming U.S. product launches across key rare disease programs including BBP-418, encaleret, and infigratinib. The market takeaway is a classic biotech capital structure tradeoff: dilution today in exchange for accelerated commercial readiness tomorrow. With multiple late-stage catalysts stacked within a 12-month window, sentiment is increasingly tied to execution probability rather than just pipeline optionality.
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:47 PM
$BBIO (-0.3% pre) BridgeBio gets $1B from Sixth Street, HCRx for three launches https://ooc.bz/l/106641
0 · Reply
Nomorelies
Nomorelies Jul. 1 at 12:32 PM
$BBIO Buy!
0 · Reply
G101SPM
G101SPM Jul. 1 at 11:41 AM
$BBIO $75.000 bid https://stocktwits.com/G101SPM/message/640618387 BRIEF: Co announced that it has entered into an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR (KKR) under which the Purchasers have invested up to $1 billion in newly issued convertible preferred equity of the Company. The Series A Cumulative Convertible Participating Preferred Stock has the following principal terms: 7.00% initial dividend, payable in kind or in cash at the Company's election Initial conversion price of $137.79 per share (more than 100% premium to BridgeBio's 30-day volume-weighted average price), increasing to $153.10 per share (more than 125% premium) from the fifth anniversary Permanent equity with no scheduled maturity and no redemption at the holder's option BridgeBio may redeem the preferred stock for cash or, in certain circumstances, convert it into common stock, in each case on the terms set forth in the definitive agreements Sixth Street funded $800M as the lead investor, and HealthCare Royalty funded $133.9M at today's close of the preferred equity investment.
0 · Reply
sampeper
sampeper Jul. 1 at 9:52 AM
$BBIO Breaking news: BridgeBio Preferred Equity Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity https://news.futunn.com/en/post/75380761/market-chatter-kkr-sixth-street-to-invest-1-billion-in?level=1&data_ticket=1782899461415526
0 · Reply
Dirtyari
Dirtyari Jul. 1 at 3:12 AM
$BBIO fasten your seat belts ;)
0 · Reply
LMXPERTEN
LMXPERTEN Jun. 30 at 5:54 PM
$BBIO we are on our way. Its only up. Remember what i told you about leaving lower levels behind 😇
0 · Reply
Laynester
Laynester Jun. 30 at 4:43 PM
$BBIO SCANNER 'BOTTOM UP' BIG BUY TODAY. Bears, Sell Calls, Buy Puts please document your BEAR CASE. MASSIVE PORTFOLIO BOTTOM UP SCANNER BUYS today. All (any) national Patriot un predjudice Men secure your FAMILY, HOME, TOWN, STATE, BORDER and all FUTURE ELECTIONS. Please join us world slaves and defeit the global elite. JOIN US world national patriotic non predjudice men and women and make a buy let's stick together...always...Remember. All for one! and One for all! Lets Roll! Set a stop. Good to all us world slaves. 100%--->🦬
0 · Reply
Cap_00
Cap_00 Jun. 30 at 2:19 PM
$BBIO Someone could buy this and plug their revenue hole and call it a day.
1 · Reply
Nomorelies
Nomorelies Jun. 29 at 11:58 PM
$BBIO GO!!!
0 · Reply
Nasdaq_Frontier
Nasdaq_Frontier Jun. 29 at 11:31 PM
In Seach of Value: Biotech: $INSM $155 $BBIO $100 $IDYA $50 $PRAX $700 This biotech list reflects ongoing market interest in the re-rating of innovation-driven drug development. INSM, BBIO, IDYA, and PRAX are all classic clinical-stage biotech companies, where the core thesis is not current earnings, but future valuation expansion driven by clinical data and pipeline execution. Key factors in biotech investing: 👉 Strength and consistency of clinical data 👉 Differentiation of the pipeline 👉 Clear and achievable commercialization path This sector is highly volatile, but successful clinical or regulatory breakthroughs can lead to significant valuation upside. Unlike AI or semiconductors, biotech is not a linear growth story—it is an event-driven sector where key milestones define outcomes. Do you prefer more established commercial names like INSM, or higher-beta clinical-stage plays like PRAX? Let’s discuss
0 · Reply
greensmell
greensmell Jun. 29 at 2:35 PM
$BBIO Should trade at $80+ given the PR
0 · Reply
G101SPM
G101SPM Jun. 29 at 10:17 AM
$BBIO $70.60 bid. Holding long position at $24.20. EXIT $125.00 note: Legacy Holding https://stocktwits.com/G101SPM/message/640618387 BRIEF: BridgeBio Pharma announced Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia were published in The New England Journal of Medicine and presented at ICCBH 2026. Co said the study met its primary endpoint, demonstrating a statistically significant improvement in annualized height velocity versus placebo (+1.74 cm/yr LS mean; p<0.0001), while also meeting key secondary endpoints including height Z-score improvement. Co said infigratinib also became the first therapy in a placebo-controlled Phase 3 achondroplasia study to demonstrate statistically significant improvements in body proportionality and arm span, with no treatment-related serious adverse events or discontinuations reported. Co intends to submit an NDA to the FDA in 3Q26 and an MAA to the EMA in 2H26, with a potential U.S. launch anticipated in early to mid-2027.
0 · Reply
sampeper
sampeper Jun. 29 at 8:52 AM
$BBIO BridgeBio Pharma, Inc.(NasdaqGS:BBIO) added to Russell 1000 Value Benchmark https://www.marketscreener.com/news/bridgebio-pharma-inc-nasdaqgs-bbio-added-to-russell-1000-value-benchmark-ce7f5fdedc8df02c
0 · Reply